EB201
Systemic Lupus Erythematosus (SLE)
DiscoveryNot yet in clinical trials
Key Facts
Indication
Systemic Lupus Erythematosus (SLE)
Phase
Discovery
Status
Not yet in clinical trials
Company
About Estrella Immunopharma
Estrella Immunopharma's mission is to extend the curative power of T-cell therapies to a broader range of cancers and autoimmune diseases by addressing the critical limitations of current CAR-T products. The company has achieved an 83% overall response rate in a proof-of-concept study for B-cell lymphoma with its lead ARTEMIS candidate, EB103, and reported no severe CRS. Its strategy involves first advancing its CD19-targeted programs in hematologic malignancies, then leveraging a unique oncolytic virus-based 'mark-and-kill' platform to tackle the vast solid tumor market, while also exploring applications in autoimmune conditions like lupus.
View full company profileTherapeutic Areas
Other Systemic Lupus Erythematosus (SLE) Drugs
| Drug | Company | Phase |
|---|---|---|
| hCDR1 (Edratide) | XTL Biopharmaceuticals | Phase 2 |
| Nipocalimab | Johnson and Johnson Innovative Medicine | Phase 3 |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| IFNα Kinoid (IFN-K) | Neovacs | Phase IIb |
| Brepocitinib (PF-06700841) | Priovant Therapeutics | Phase 3 |
| aiSLE® DX Flare Risk Index | Progentec Diagnostics | Commercial |
| aiSLE® DX Disease Activity Index | Progentec Diagnostics | Commercial |
| OASIS Study (Digital Biomarkers) | Progentec Diagnostics | Clinical Study |
| RSLV-132 | Resolve Therapeutics | Phase 2 |
| Mini-CAR for SLE | Caravan Biologix | Pre-clinical |
| Internal Program | BenevolentAI | Preclinical |
| Cenerimod | Ono Pharmaceutical | Phase 3 |